A multicenter, single-arm phase II trial of bevacizumab beyond initial progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in Advanced Colorectal Cancer

Interventions: bevacizumab plus mFOLFOX6 therapy (first-line treatment) bevacizumab plus FOLFIRI therapy (second-line treatment)
Primary outcome(s): 2nd progression free survival (2nd PFS)
Study Design: Single arm Non-randomized